Science ·
UK medicines regulator starts programme to improve evidence for women’s health
The November 16 launch addresses research gaps, including limited representation during pregnancy and breastfeeding.
Nashville Globe · News Desk
The UK medicines regulator launched a Women’s Health Programme on November 16 to improve evidence used in regulating medicines and medical devices. The Medicines and Healthcare products Regulatory Agency plans to work with patients, researchers, clinicians and industry on how product benefits and risks can differ for women.
The agency examined 4,616 UK clinical trial applications submitted between 2019 and 2023. It reported that pregnant women were represented in 1.1% of trials and breastfeeding women in 0.6%. Those figures describe representation across the trials analysed; they are not percentages of all individual trial participants.
Patients helped shape the programme through the agency’s public community and a Patients Association focus group. The initiative forms part of its wider work on health inequalities and its strategy to 2030. The launch announces a regulatory research programme, rather than approval of a particular treatment. Its stated aim is stronger evidence while maintaining standards for safety, quality and effectiveness.